Bibliografisk note

Funding Information:
Acknowledgments. The authors thank all investigators, staff, and participants of this study. The authors also thank Rikke Baastrup Nordsborg and Usha Thamattoor for data analysis, Charlotte Højelse for study management, and Pranav Kelkar and Renuka Munik-rishnappa, all from Novo Nordisk, for the input into the manuscript. Medical writing and editorial assistance were provided by Jane Blackburn, Amy Hepple, and Helen Marshall of Ashfield MedComms, an Ashfield Health company, funded by Novo Nordisk A/S. A complete list of the investigators in the EVOLVE study can be found in the Supplementary Material. Funding. The EVOLVE study, including study design, data collection, analysis, and interpretation, was funded by Novo Nordisk A/S. Medical writing and editorial assistance were also sponsored by Novo Nordisk A/S. Duality of Interest. E.R.M. has received speakers fees from Novo Nordisk, Eli Lilly and Company, and Sanofi Aventis; has participated in steering committee tasks and guidance involving writing protocols for Novo Nordisk; is participating in several multinational clinical studies on the use of insulin in pregnant women with pre-existing diabetes, in collaboration with Novo Nordisk. K.C. has received speaker honoraria from or has participated in advisory boards for Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZe-neca, Boehringer Ingelheim, and Servier. J.D. has received speaker honoraria from or has participated in advisory boards for Novo Nordisk, Eli Lilly and Company, Sanofi, Amgen, Abbott, Astra-Zeneca, Boehringer Ingelheim, Mundipharma, and Merck Sharp & Dohme. A.C.A., M.-A.G., and L.L.N.H. are employees of, and hold shares in, Novo Nordisk. S.D.G. is a consultant for Sanofi, Eli Lilly and Company, Novo Nordisk, Takeda Pharmaceutical Company, Merck Sharp & Dohme, Servier, and Theracos. H.P.H. has received lecturer and scientific advisor fees from Abbott, AstraZeneca, Eli Lilly and Company, Insu-let, LifeScan, and Novo Nordisk and research grants from Abbott, LifeScan, and Novo Nordisk. H.-P.K. has received speaker honoraria from, or has participated in advisory boards for, Novo Nordisk, Eli Lilly and Company, Sanofi, Astra-Zeneca, and Servier. D.R.M. has received speaker honoraria from, or has participated in advisory boards for, Novo Nordisk. P.D. is participating in clinical studies on the use of insulin analogs in pregnant women with preexisting diabetes and participates in an expert committee on this topic, in collaboration with Novo Nordisk, no personal honorarium is involved. No other potential conflicts of interest relevant to this article were reported. Author Contributions. E.R.M., N.A., A.C.A., E.A., K.C., H.d.V., J.D., F.D., M.-A.G., S.D.G., H.P.H., L.L.N.H., M.I., H.-P.K., D.R.M., and P.D. all interpreted results and provided input, critical review, and approval for the manuscript. All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. E.R.M. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Prior Presentation. This work was presented in poster form at the 80th Scientific Sessions of the American Diabetes Association, 12–16 June 2020, and in oral form at the 56th Annual Meeting of the European Association for the Study of Diabetes, 21–25 September 2020.

Publisher Copyright:
© 2021 by the American Diabetes Association.